Literature DB >> 7958675

Escherichia coli heat-stable toxin receptors in human colonic tumors.

S L Carrithers1, S J Parkinson, S Goldstein, P Park, D C Robertson, S A Waldman.   

Abstract

BACKGROUND/AIMS: Escherichia coli heat-stable enterotoxins (ST) are small peptides of 18 or 19 amino acids that bind to specific cell surface receptors located on the intestinal brush border and activate guanylate cyclase, resulting in an increase in the intracellular cyclic guanosine 3',5'-monophosphate content of the cell. The present study examined whether receptors for ST are expressed by primary and metastatic human colonic tumors in vivo.
METHODS: Plasma membranes prepared from surgical tissue samples from normal colon, liver and lung, primary colonic adenocarcinomas, and colon carcinomas metastatic to lung and liver were analyzed for the structural and functional characteristics of constituent ST receptors.
RESULTS: All primary and metastatic colonic tumors examined bound ST, showing receptors of high (pmol/L) and low (nmol/L) affinity with densities that were similar to those in normal colon. Also, affinity cross-linking of labeled ST to membranes showed similar binding proteins in primary and metastatic tumors and normal colon. ST binding and affinity-labeled proteins were not detected in normal extraintestinal tissues. Guanylate cyclase was activated by ST in membranes from all colonic tumors studied, with efficacies and potencies that were similar to those in normal colon. ST did not activate this enzyme in normal extraintestinal tissues.
CONCLUSIONS: Receptors for ST are expressed by primary and metastatic human colonic tumors in vivo, with structural and functional characteristics that are similar to those in normal human colon.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7958675     DOI: 10.1016/0016-5085(94)90804-4

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  38 in total

1.  Molecular staging estimates occult tumor burden in colorectal cancer.

Authors:  Alex Mejia; Stephanie Schulz; Terry Hyslop; David S Weinberg; Scott A Waldman
Journal:  Adv Clin Chem       Date:  2010       Impact factor: 5.394

2.  Sex modulates intestinal transformation by the tumor-suppressor GCC.

Authors:  Peng Li; Stephanie Schulz; Giovanni M Pitari; Scott A Waldman
Journal:  Clin Transl Sci       Date:  2008-09       Impact factor: 4.689

3.  Sex modulates intestinal transformation by the tumor-suppressor GCC.

Authors:  Peng Li; Stephanie Schulz; Giovanni M Pitari; Scott A Waldman
Journal:  Clin Transl Sci       Date:  2008-09       Impact factor: 4.689

Review 4.  Regulation and therapeutic targeting of peptide-activated receptor guanylyl cyclases.

Authors:  Lincoln R Potter
Journal:  Pharmacol Ther       Date:  2010-12-24       Impact factor: 12.310

Review 5.  GUCY2C ligand replacement to prevent colorectal cancer.

Authors:  Erik S Blomain; Amanda M Pattison; Scott A Waldman
Journal:  Cancer Biol Ther       Date:  2016-04-22       Impact factor: 4.742

Review 6.  Molecular staging individualizing cancer management.

Authors:  Alex Mejia; Stephanie Schulz; Terry Hyslop; David S Weinberg; Scott A Waldman
Journal:  J Surg Oncol       Date:  2012-04-01       Impact factor: 3.454

Review 7.  GUCY2C molecular staging personalizes colorectal cancer patient management.

Authors:  Jian P Gong; Stephanie Schulz; Terry Hyslop; Scott A Waldman
Journal:  Biomark Med       Date:  2012-06       Impact factor: 2.851

Review 8.  Immunotherapeutic strategies to target prognostic and predictive markers of cancer.

Authors:  Michael S Magee; Adam E Snook; Glen P Marszalowicz; Scott A Waldman
Journal:  Biomark Med       Date:  2013-02       Impact factor: 2.851

Review 9.  GCC signaling in colorectal cancer: Is colorectal cancer a paracrine deficiency syndrome?

Authors:  P Li; J E Lin; G P Marszlowicz; M A Valentino; C Chang; S Schulz; G M Pitari; Scott A Waldman
Journal:  Drug News Perspect       Date:  2009 Jul-Aug

10.  Topological mimicry and epitope duplication in the guanylyl cyclase C receptor.

Authors:  A Nandi; K Suguna; A Surolia; S S Visweswariah
Journal:  Protein Sci       Date:  1998-10       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.